Trial Profile
A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary) ; Nazartinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Farma; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 28 Jun 2022 Status changed from recruiting to discontinued.
- 23 Jun 2022 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 06 Jun 2022 This trial has been Discontinued in Germany, according to European Clinical Trials Database record.